Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (381-390 of 484) with videos related to

Pageof 49
Sort By:
Urology|July 25, 2016
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary CareE David Crawford, Matt T Rosenberg, Alan W Partin, et al.
Journal of the National Cancer Institute|September 13, 2007
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention TrialM Scott Lucia, Jonathan I Epstein, Phyllis J Goodman, et al.
JU Open Plus|February 19, 2026
Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate CancerNicholas W Eyrich, Yijian Huang, Yingye Zheng, et al.
European Urology|February 14, 2018
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance OutcomesMatthew R Cooperberg, James D Brooks, Anna V Faino, et al.
Oncotarget|February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancerDebashis Sahoo, Wei Wei, Heidi Auman, et al.
Carcinogenesis|July 21, 2011
Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention TrialLi Tang, Song Yao, Cathee Till, et al.
The Lancet. Oncology|July 23, 2013
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialDavid I Quinn, Catherine M Tangen, Maha Hussain, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 31, 2015
Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention TrialTeemu J Murtola, Bora Gurel, Martin Umbehr, et al.
European Urology|July 6, 2023
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
European Urology Focus|September 13, 2016
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate CancerTamara L Lotan, Wei Wei, Carlos L Morais, et al.
Pageof 49

Showing results (381-390 of 484) with videos related to

Sort By:
Pageof 49
Urology|July 25, 2016
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary CareE David Crawford, Matt T Rosenberg, Alan W Partin, et al.
Journal of the National Cancer Institute|September 13, 2007
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention TrialM Scott Lucia, Jonathan I Epstein, Phyllis J Goodman, et al.
JU Open Plus|February 19, 2026
Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate CancerNicholas W Eyrich, Yijian Huang, Yingye Zheng, et al.
European Urology|February 14, 2018
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance OutcomesMatthew R Cooperberg, James D Brooks, Anna V Faino, et al.
Oncotarget|February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancerDebashis Sahoo, Wei Wei, Heidi Auman, et al.
Carcinogenesis|July 21, 2011
Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention TrialLi Tang, Song Yao, Cathee Till, et al.
The Lancet. Oncology|July 23, 2013
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialDavid I Quinn, Catherine M Tangen, Maha Hussain, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 31, 2015
Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention TrialTeemu J Murtola, Bora Gurel, Martin Umbehr, et al.
European Urology|July 6, 2023
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
European Urology Focus|September 13, 2016
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate CancerTamara L Lotan, Wei Wei, Carlos L Morais, et al.
Pageof 49